Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss widened to $73.6M from $42.2M, reflecting accelerated Phase 3 enrollment and commercialization preparation
- Cash, equivalents and marketable securities declined to $413.8M from $505.4M at December 31, 2025
- OPERA-01 Phase 3 top-line data remains targeted for Q1 2027, the company’s key near-term valuation catalyst
- OPERA-02 and OP-3136 enrollment continued, expanding potential indications but increasing near-term cash burn
- Jason O’Byrne appointed CFO, adding capital-markets and financial-management experience ahead of 2027 catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.